Daiichi Sankyo, Inc., the US subsidiary of Daiichi Sankyo Company, Ltd, will merge with its US-based sister company, Asubio Pharmaceuticals, Inc. As a result, Asubio Pharmaceuticals, Inc. projects will be integrated into the Daiichi Sankyo global development organization, led by Mahmoud Ghazzi, MD, PhD. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of Japan’s Daiichi Sankyo Group.

Asubio Pharmaceuticals’ parent company, Asubio Pharma Co., Ltd, which is based in Japan, will continue to operate as a wholly owned subsidiary of Daiichi Sankyo Co., Ltd., with a focus on discovery research. Asubio Pharmaceuticals, Inc.’s ongoing clinical trial in patients with acute spinal cord injury has completed enrollment. An analysis and dissemination of the data will be managed by Daiichi Sankyo.

Source: Daiichi Sankyo Inc.